First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

First-Line Extensive-Stage Small Cell Lung Cancer:
Examining the New Role of Combination Chemotherapy and Immunotherapy

Date: Wednesday, October 28, 2020
Time: 8:00 PM EDT

Register today
Join an expert panel in thoracic oncology featuring; Kathryn Gold, MD, Taofeek Owonikoko, MD, Taofeek Owonikoko, MD, Konstantinos Leventakos, M.D., Ph.D. as they discuss how to navigate the new role of I/O therapy in combination with chemotherapy for the first-line treatment of ES-SCLC and questions surrounding how to use this approach in clinical practice.

Attend this special event to have a better understanding of:

  • Characteristics of small cell lung cancer
  • How SCLC and NSCLC are differentiated in clinical practice
  • The need for rapid treatment response to ES-SCLC
  • The role of combination chemotherapy + I/O therapy in first-line ES-SCLC
  • Clinical trials for IO + chemotherapy combinations
    Standard first-line approach
  • Patient involvement in treatment​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


    Moderator:

Kathryn Gold, MD
Associate Professor and Vice Chief
Division of Hematology and Oncology
UC San Diego Moores Cancer Cancer
San Diego, California

Panelists:

Taofeek Owonikoko, MD
Professor and Vice Chair for Faculty Development
Hematology and Medical Oncology
Emory University
Atlanta, GA

Konstantinos Leventakos, M.D., Ph.D.
Oncologist
Mayo Clinic
Rochester, MN
Sponsored By: